Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
298 GBX | +1.02% | -7.74% | -15.46% |
Apr. 02 | MaxCyte inks deal with Be Bio; Orcadian firms farmout | AN |
Apr. 02 | MaxCyte, Inc. Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.46% | 387M | |
+8.04% | 220B | |
+6.18% | 183B | |
+10.13% | 133B | |
+25.51% | 107B | |
-1.83% | 63.05B | |
+13.06% | 51.74B | |
+3.96% | 50.47B | |
+0.05% | 40.91B | |
+24.10% | 31.91B |
- Stock Market
- Equities
- MXCT Stock
- News MaxCyte, Inc.
- MaxCyte Reaffirms Fiscal 2023 Revenue Guidance